In early 2024, Uganda once again faced an outbreak of Ebola virus infections, this time involving the Sudan strain.The initial case—a nurse in the capital city of Kampala—tragically led to additional infections among close contacts. This incident reignited global attention on the Ebola virus and highlighted the ongoing risk posed by emerging and re-emerging pathogens. In response, Ugandan health authorities, in coordination with the World Health Organization, launched clinical trials targeting the Sudan strain, reinforcing the critical need for rapid diagnostics, effective vaccines, and a deeper molecular understanding of the virus.
The Ebola virus is a filamentous virus belonging to the Filoviridae family and is among the largest in this group. Its virions are long, thread-like structures with a diameter of approximately 100 nm and lengths ranging from 300 to 970 nm. The viral particle is enveloped by a lipid membrane embedded with glycoprotein spikes, which are essential for host cell binding and viral entry. Beneath the envelope lies the nucleocapsid, composed of nucleoprotein (NP), viral RNA, polymerase protein (L), and structural proteins VP35 and VP40. This complex structure enables the virus to replicate and transcribe efficiently inside host cells.
Key Viral Proteins and Their Functions
Glycoprotein (GP): The only envelope protein on the viral surface, GP mediates host cell attachment and membrane fusion. It consists of GP1 (receptor binding) and GP2 (membrane fusion) subunits. After endocytosis, GP1 is processed in the endosome, exposing the RBS domain for NPC1 binding, followed by GP2-triggered fusion.
Nucleoprotein (NP): NP is the most abundant protein in the virus, responsible for binding viral RNA to form the ribonucleoprotein complex (RNP). It protects RNA from degradation and facilitates replication and transcription.
Polymerase (L): The L protein is the RNA-dependent RNA polymerase essential for viral genome replication and transcription. It is a highly conserved target for antiviral drug development. Its complex structure was first resolved by a Chinese research team in 2022, offering insights into Ebola’s replication mechanism.
VP24: This protein suppresses host interferon responses by blocking nuclear import pathways and inhibiting key transcription factors. VP24 is also involved in viral assembly.
VP30: A transcription activator that works with NP and L to initiate viral mRNA synthesis.
VP35: A multifunctional cofactor that inhibits host immune responses and supports RNA synthesis in coordination with NP and L.
VP40: The matrix protein responsible for virion assembly and budding. It interacts with the host membrane to facilitate virus release and influences infectivity.
Ebola Vaccine Development Highlights
rVSV-ZEBOV (Merck): Demonstrated 84% efficacy when administered at least 10 days before exposure, based on outbreak data in Congo.
eVLVs (Wuhan Institute of Virology, CAS): A replication-competent vaccine candidate expressing GP and VP40, offering full protection in mice after a single dose.
Sudan Strain Vaccine Trial: A global-first clinical trial in Uganda is underway, targeting contacts of confirmed Sudan strain cases in collaboration with WHO and national health bodies.
abinScience Research Reagents for Ebola Virus
As a core brand under ProteoGenix, abinScience is committed to developing and supplying high-quality research reagents to scientists worldwide. With a comprehensive inventory of viral proteins and antibodies, including those for Ebola virus, our reagents enable cutting-edge virology, immunology, and vaccine research.
Available products include recombinant GP, NP, VP35, VP40 proteins and corresponding monoclonal antibodies. Contact us for detailed product lists or custom solutions.
| Type |
Catalog No. |
Product Name |
| Protein |
VK512012 |
Recombinant Zaire ebolavirus NP/Nucleoprotein Protein, C-His |
| VK623042 |
Recombinant TAFV GP1 Protein, N-His |
| VK623091 |
Recombinant TAFV GP1 Protein, C-Fc |
| VK623081 |
Recombinant TAFV GP1 Protein, C-His |
| VK623022 |
Recombinant REBOV GP1 Protein, N-His |
| VK623051 |
Recombinant REBOV GP1 Protein, C-Fc |
| VK623041 |
Recombinant REBOV GP1 Protein, C-His |
| VK623012 |
Recombinant ZEBOV GP1 Protein, N-His |
| VK623031 |
Recombinant ZEBOV GP1 Protein, C-Fc |
| VK623021 |
Recombinant ZEBOV GP1 Protein, C-His |
| VK623011 |
Recombinant ZEBOV GP/GP1,2 Protein, C-His |
| VK623061 |
Recombinant SEBOV GP1 Protein, C-His |
| VK623071 |
Recombinant SEBOV GP1 Protein, C-Fc |
| VK623032 |
Recombinant SEBOV GP1 Protein, N-His |
| Antibody |
VK623016 |
Research Grade Larcaviximab |
| VK623026 |
Research Grade Odesivimab |
| VK623036 |
Research Grade Cosfroviximab |
| VK623046 |
Research Grade Porgaviximab |
| VK623056 |
Research Grade Maftivimab |
| VK623066 |
Research Grade Atoltivimab |
| VK623076 |
Research Grade Ansuvimab |
| VK623106 |
Research Grade Anti-REBOV/SEBOV/TAFV/ZEBOV GP/Envelope glycoprotein Antibody (ADI-15878) |
| VK623010 |
InVivoMAb Anti-ZEBOV GP/Envelope glycoprotein Antibody(lv0195) |
| VK623020 |
InVivoMAb Anti-ZEBOV GP/Envelope glycoprotein Antibody(lv0196) |
| VK623030 |
InVivoMAb Anti-ZEBOV GP/Envelope glycoprotein Antibody(lv0197) |
| VK623040 |
InVivoMAb Anti-ZEBOV GP/Envelope glycoprotein Antibody(6D8) |
| VK623050 |
InVivoMAb Anti-SEBOV/ZEBOV GP/Envelope glycoprotein Antibody(Iv0198) |
| VK518010 |
InVivoMAb Anti-REBOV/SEBOV/TAFV/ZEBOV NP/Nucleoprotein Antibody(MJ20) |
| VK661013 |
Anti-ZEBOV VP35/Polymerase cofactor VP35 Antibody(F9) |
| VK783013 |
Anti-ZEBOV VP40/Matrix protein VP40 Antibody(DSTL094) |
| VK591013 |
Anti-SEBOV RNA-directed RNA polymerase L/Protein L Nanobody(SAA1489) |
| VK518013 |
Anti-Sudan ebolavirus/SEBOV NP/Nucleoprotein Antibody(SAA1402) |
| VK518023 |
Anti-ZEBOV NP/Nucleoprotein Antibody(KZ51) |
| VK623013 |
Anti-Zaire ebolavirus/ZEBOV GP/GP1,2 Nanobody(SAA1248) |
| VK623023 |
Anti-ZEBOV GP/Envelope glycoprotein Antibody(mAb100) |
| VK623033 |
Anti-SEBOV GP/Envelope glycoprotein Antibody(16F6) |
| VK623043 |
Anti-ZEBOV GP/Envelope glycoprotein Antibody(GPE118) |
| VK512014 |
Anti-Zaire ebolavirus NP/Nucleoprotein Polyclonal Antibody |
